Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LCTX 
Lineage Cell Therapeutics Inc (LCTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: LCTX (1-star) is a SELL. SELL since 5 days. Profits (3.16%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.17
1 Year Target Price $4.17
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.31% | Avg. Invested days 20 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 232.92M USD | Price to earnings Ratio - | 1Y Target Price 4.17 |
Price to earnings Ratio - | 1Y Target Price 4.17 | ||
Volume (30-day avg) 7 | Beta 1.66 | 52 Weeks Range 0.37 - 1.31 | Updated Date 08/15/2025 |
52 Weeks Range 0.37 - 1.31 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.03 | Actual -0.13 |
Profitability
Profit Margin - | Operating Margin (TTM) -178.66% |
Management Effectiveness
Return on Assets (TTM) -13.17% | Return on Equity (TTM) -71.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 192789415 | Price to Sales(TTM) 21.34 |
Enterprise Value 192789415 | Price to Sales(TTM) 21.34 | ||
Enterprise Value to Revenue 17.66 | Enterprise Value to EBITDA -8.84 | Shares Outstanding 228356000 | Shares Floating 177740893 |
Shares Outstanding 228356000 | Shares Floating 177740893 | ||
Percent Insiders 0.42 | Percent Institutions 41.35 |
Upturn AI SWOT
Lineage Cell Therapeutics Inc
Company Overview
History and Background
Lineage Cell Therapeutics Inc, formerly BioTime, Inc., was founded in 1990. The company focuses on developing and commercializing novel cell therapies for unmet medical needs. Significant milestones include clinical trials for spinal cord injury and age-related macular degeneration.
Core Business Areas
- Ophthalmology: Development of cell therapies for age-related macular degeneration (AMD), including OpRegen.
- Spinal Cord Injury: Development of OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injury.
- Cell Therapy Manufacturing: Manufacturing and commercialization of cell therapy products and technologies.
Leadership and Structure
Brian M. Culley is the Chief Executive Officer. The organizational structure includes research and development, clinical operations, and manufacturing departments.
Top Products and Market Share
Key Offerings
- OpRegen: A retinal pigment epithelium (RPE) cell therapy in Phase 2b clinical trials for dry age-related macular degeneration (AMD) with geographic atrophy. Market share is currently minimal as it's still in development. Competitors include Apellis (APLS) with Syfovre and Iveric Bio (ISEE) which was acquired by Astellas Pharma Inc. (ALPMY). No current revenue
- OPC1: An oligodendrocyte progenitor cell (OPC) therapy in clinical development for acute spinal cord injury. Market share is currently minimal as it's still in development. Few direct competitors given the specific target and the focus in the acute spinal cord injury area, but potential competitors can be Vertex Pharmaceuticals (VRTX) and Neuronyx. No current revenue
Market Dynamics
Industry Overview
The cell therapy industry is experiencing rapid growth, driven by advancements in regenerative medicine and the potential to treat previously incurable diseases. However, it is high-risk/high reward. Development, regulatory, and manufacturing hurdles remain significant.
Positioning
Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on cell therapies. Its competitive advantage lies in its proprietary cell therapy platforms and clinical trial progress in high-unmet-need areas.
Total Addressable Market (TAM)
The total addressable market for AMD and spinal cord injury therapies is estimated to be in the billions of dollars annually. Lineage is positioned to capture a portion of this TAM if its therapies are successfully developed and commercialized.
Upturn SWOT Analysis
Strengths
- Proprietary cell therapy platforms
- Clinical-stage assets in high-unmet-need areas
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- High clinical trial risk
- Dependence on successful clinical trial outcomes
- Manufacturing complexities
Opportunities
- Positive clinical trial results
- Partnerships and collaborations
- Regulatory approvals
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Competition from other cell therapy companies
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- APLS
- ALPMY
- VRTX
Competitive Landscape
Lineage Cell Therapeutics competes in the cell therapy market, facing competition from established pharmaceutical companies and other biotechnology firms. The company needs to secure regulatory approvals and secure finances.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is unavailable at this time and insufficient data provided.
Future Projections: Future growth projections are based on analyst estimates. These estimates vary and are subject to change.
Recent Initiatives: Recent initiatives include advancing clinical trials for OpRegen and OPC1, securing partnerships, and optimizing manufacturing processes.
Summary
Lineage Cell Therapeutics is a clinical-stage biotech firm with a focus on cell therapies for AMD and spinal cord injury. The company's success hinges on positive clinical trial results and regulatory approvals. Financial resources remain a key challenge and it depends on successful outcomes. The market landscape is competitive, requiring strategic execution to capitalize on opportunities and mitigate threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lineage Cell Therapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary based on source and methodology. Clinical trial outcomes are inherently uncertain.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lineage Cell Therapeutics Inc
Exchange NYSE MKT | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 1992-03-06 | CEO, President & Director Mr. Brian M. Culley M.A., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://www.lineagecell.com |
Full time employees 70 | Website https://www.lineagecell.com | ||
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.